Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.175
https://www.valueinhealthjournal.com/article/S1098-3015(13)02080-9/fulltext
Title : Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02080-9&doi=10.1016/j.jval.2013.08.175
First page : A352
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 161
Categories :
Tags :
Regions :
ViH Article Tags :